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Abstract
The cellular prion protein (PrPC) has been extensively studied because of its pivotal role in
prion diseases; however, its functions remain incompletely understood. A unique line of
goats has been identified that carries a nonsense mutation that abolishes synthesis of PrPC.
In these animals, the PrP-encoding mRNA is rapidly degraded. Goats without PrPC are valu-
able in re-addressing loss-of-function phenotypes observed in Prnp knockout mice. As PrPC
has been ascribed various roles in immune cells, we analyzed transcriptomic responses to
loss of PrPC in peripheral blood mononuclear cells (PBMCs) from normal goat kids (n = 8,
PRNP+/+) and goat kids without PrPC (n = 8, PRNPTer/Ter) by mRNA sequencing. PBMCs
normally express moderate levels of PrPC. The vast majority of genes were similarly
expressed in the two groups. However, a curated list of 86 differentially expressed genes
delineated the two genotypes. About 70% of these were classified as interferon-responsive
genes. In goats without PrPC, the majority of type I interferon-responsive genes were in a
primed, modestly upregulated state, with fold changes ranging from 1.4 to 3.7. Among these
were ISG15, DDX58 (RIG-1), MX1, MX2, OAS1, OAS2 and DRAM1, all of which have
important roles in pathogen defense, cell proliferation, apoptosis, immunomodulation and
DNA damage response. Our data suggest that PrPC contributes to the fine-tuning of resting
state PBMCs expression level of type I interferon-responsive genes. The molecular mecha-
nism by which this is achieved will be an important topic for further research into PrPC
physiology.
Introduction
The cellular prion protein (PrPC) can misfold into disease-provoking conformers (PrP scrapie;
PrPSc) that give rise to several neurodegenerative prion diseases, such as Creutzfeldt-Jakob dis-
ease (CJD) in humans, scrapie in sheep and goats, and bovine spongiform encephalopathy in
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cattle [1]. The seeding of PrPSc in brain tissue acts as a template for further misfolding of PrPC,
ultimately leading to severe neurodegeneration and neuronal death [1].
PrPC is abundant throughout the nervous system, and, albeit at lower levels, in most other
tissues of the body [2]. The protein is conserved in mammalian species [3, 4] and expressed
already during early embryonal stages [5]. It was therefore surprising that Prnp0/0 mice devel-
oped normally and revealed no major phenotypes besides being prion-disease resistant [6–8].
Interestingly, in four Prnp0/0 mouse models (Ngsk, Rcm0, ZrchII, and Rikn), ablation of the
Prnp gene induced severe degeneration of cerebellar Purkinje neurons [9–12]. This was, how-
ever, subsequently shown to be caused by ectopic expression of the prion-like protein Doppel
(Dpl) in the brain, as a side-effect of the transgenic protocols [10]. Two additional Prnp-ablated
mouse lines (ZrchI and Npu) displayed no neurodegeneration [7, 8]. Furthermore, other
experiments have shown that a polymorphism in another Prnp flanking gene, Sirp-alpha,
could significantly influence the interpretation of data that concerns the roles for PrPC in
phagocytosis [13]. Despite these inherent challenges with Prnp-null models [14], collectively
known as the flanking-gene problem, the Prnp0/0 lines have proven extremely valuable in
exploring PrPC physiology. They have provided clues regarding maintenance of axonal myelin
[15–17], modulation of circadian rhythms [18], and neuronal excitability [19], in addition to
protective roles in severe stress such as ischemia [20] and hypoxic brain damage [21].
A more general problem is the gap between mice and human physiologies [22–24]. The two
species diverged about 65 million years ago, and differ substantially in both size and life span.
Mice have evolved into short-lived animals relying on massive reproductive capacity, whereas
humans reside at the other end of the spectrum, with low reproduction rates and life spans of
approximately 80 years. This is of particular significance in modeling chronic human diseases
that take decades to develop, and often involve subtle immunological imbalances [22]. In addi-
tion, translation to human medicine has proven challenging.
Recently, we identified what seems to be a unique line of dairy goats carrying a nonsense
mutation that completely abolishes synthesis of PrPC [25]. This spontaneous, non-transgenic
model, is referred to as PRNPTer/Ter. Approximately 10 percent of the Norwegian dairy goat
population carries the mutated allele. These animals appear to have normal fertility and behav-
ior in all aspects of standard husbandry. We have no data to suggest that they are over-repre-
sented in disease statistics or otherwise failing in production performance. Careful analysis of
hematological and blood biochemical parameters, as well as basic immunological features, did
not reveal any abnormalities [26]. It was, however, noted that goats without PrPC had slightly
elevated numbers of red blood cells, identical to an observation in transgenic cattle without
PrPC [27], suggesting that this is a true biological loss-of-function phenotype, at least in
ruminants.
Peripheral blood mononuclear cells (PBMCs) express moderate, but dynamic, levels of
PrPC [28]. We observed that goats heterozygous for the mutation (PRNP+/Ter) express half
the amount of cell surface PrPC on PBMCs [26]; however, a 50 percent reduction in levels
compared to PBMCs from PRNP+/+ goats did not stimulate compensatory expression from
the normal allele. Intrigued by this, and the fact that many reports have pointed to putative
functions for PrPC in immune cells (reviewed in [29], [30, 31]), mRNA sequencing of
PBMCs derived from normal goats and goats without PrPC was performed. The main goal
of this study was to evaluate whether the loss of PrPC elicits a transcriptional response in
PBMCs that could reveal biological processes involving PrPC. Our findings show that in the
absence of PrPC, a subtle, but highly significant change in the transcriptional profile of
PBMCs is seen, dominated by upregulation in the expression of type I interferon-responsive
genes.
PrPC modulates type I interferon signaling
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Results
RNA-seq data quality control
High quality RNA sequencing data (FASTQ) were derived from Beijing Genome Institute
(BGI), with an average total reads of 58,806,319 per sample, average total mapped reads of
42,168,758, and average uniquely mapped reads of 38,253,898 per sample (S1 Fig). To validate
the sequencing data, primers (S1 Table) were designed for 12 randomly selected differentially
expressed genes (DEGs), using reverse transcription (RT) quantitative real-time PCR (qPCR)
on the original RNA. As shown in Fig 1, qPCR analysis of mRNA levels correlated well with
the RNA-seq analysis (r = 0.9616, p< 0.0001, Pearson correlation). Minor discrepancies could
be due to sample variations, as RNA from only six goats per group were used for qPCR valida-
tion, compared with eight goats per group for RNA-seq analysis.
Lack of PrPC subtly alters the transcriptome in immune cells
A high correlation was observed between averaged PRNP+/+ and PRNPTer/Ter normalized gene
expression data (r = 0.99, Pearson correlation). However, we found that not all PRNP+/+ and
PRNPTer/Ter goats could be clearly separated from each other, probably reflecting the pheno-
typic diversity of the goats (S2 Fig). Despite this, using edgeR [32] and a p-value cut-off < 0.05,
735 genes were differentially expressed between the two genotypes (S1 File). Further filtration
of the gene list using cut offs for fold change (log2 FC ± 0.5) and mean number of reads (> 100
reads in one of the groups) generated a high-confidence gene list of 127 DEGs, of which 67
were upregulated and 60 were downregulated in the PRNPTer/Ter genotype (S2 Table). Of note,
as we have previously shown that the PBMC cell populations, mainly T cells, B cells and mono-
cytes, are stable between the two genotypes compared in our study [26], the DEGs result from
real genotype-associated shifts in gene expression, not shifts in the cell populations. Reassur-
ingly, the PRNP gene was among the DEGs, with very few reads mapping to this locus in the
mutant. The chromosomal distribution of the DEGs is found in S3 Fig. The PRNP gene is
located on chromosome 13 in goats. Only 1 (SIGLEC1) of the 86 annotated DEGs also maps to
Fig 1. Validation of RNA sequencing data with quantitative PCR. Validation of 12 randomly chosen,
differentially expressed genes was performed with qPCR using the original RNA. Expression data from the
two methods are presented as relative expression between PRNPTer/Ter and PRNP+/+ animals (RNA-seq data
n = 8, qPCR n = 6; r = 0.9616, p < 0.0001, Pearson correlation).
https://doi.org/10.1371/journal.pone.0179881.g001
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chromosome 13. This gene is expressed at a low level and is irrelevant for the findings in our
study.
Of the average total number of genes expressed in PBMCs from both genotypes, only 0.7
percent of the genes were altered upon loss of PrPC (Fig 2A). Using Ingenuity Pathway An-
alysis (IPA), of the 127 high-confidence DEGs, 86 genes were functionally annotated. In-
terestingly, 22 of these genes were categorized as “Viral infection” (p-value = 3.27x10-5), and
additional genes were related to other anti-virus-associated terms. The majority of these genes
were upregulated in the PRNPTer/Ter genotype compared with the PRNP+/+ genotype. Of the
top canonical pathways, “Interferon signaling” was by far the most affected (p-value = 8.92x
10-6). Due to these findings, we performed further analyses of the annotated DEGs using the
Interferome database [33]. Strikingly, 60 of the 86 annotated DEGs were interferon-responsive
genes (Fig 2B). Of these, 42 were upregulated (red bar) and 18 downregulated (blue bar) in the
PRNPTer/Ter genotype. Fig 2C shows the inter-individual variation in gene expression of all
samples represented in a heatmap, and hierarchical clustering analysis of the 60 interferon-
responsive genes revealed a clustering of downregulated and upregulated genes between the
PRNP+/+ and PRNPTer/Ter genotypes.
Since the observed data could be due to altered expression levels of interferons or compo-
nents in type I interferon signaling, we analyzed expression levels of a number of genes that
could affect the expression of interferon-responsive genes. However, differences between the
genotypes were not detected (Table 1), except for IFNB2-like, which was slightly downregu-
lated in the PRNPTer/Ter genotype (p-value = 0.025).
Introduction of PRNP inhibited MX2 gene expression in SH-SY5Y cells
To test whether PrPC could influence IFN-α responsiveness in a cell culture system with a dif-
ferent genetic makeup, we used human neuroblastoma SH-SY5Y cells, which normally express
extremely low levels of PrPC. SH-SY5Y clones stably expressing human PrPC were generated
(SH-SY5Y PrPhigh) and assessed with regard to glycosylation and proteolytic processing to
ensure physiological post-translational modification and trafficking of PrPC (S4 Fig). Eight
clones stably expressing PrPC as well as untransfected SH-SY5Y cells were exposed to 3 U/ml
IFN-α for 3h. One of the transfected clones showed aberrantly high MX2 gene expression lev-
els and was excluded from the analysis. Of the seven clones included in the experiment, six dis-
played a significantly reduced response to IFN- α, as assessed by the interferon-responsive
gene MX2 expression levels, compared with the untransfected SH-SY5Y cells, using Dunnett’s
post hoc test for multiple comparisons (Fig 3) (n = 4, mean ± SEM). The levels of PrPC expres-
sion did not directly correlate with the degree of MX2 expression-level inhibition; however,
this was not expected due to the complexity of the interferon signaling pathway, and the possi-
ble distance between PrPC interference and MX2 gene expression. On average, the clones
showed a significantly inhibited response to IFN- α (p-value = 0.0001) compared with the
untransfected SH-SY5Y cells, using a two-way ANOVA.
Increased interferon-responsive gene expression in blood leukocytes
devoid of PrPC after LPS challenge
In an independent, parallel study [34, 35], goats were challenged intravenously with lipopoly-
saccharide (LPS), thereby indirectly stimulating interferon pathways. RNA was extracted from
circulating blood leukocytes, and gene expression of interferon-responsive genes was assessed
by FLUIDIGM qPCR. As shown in Fig 4A, basal level expression (0h) of several interferon-
responsive genes was slightly higher in the PRNPTer/Ter (n = 13) genotype than in the PRNP+/+
(n = 12) genotype, albeit being significantly different for only IFI6 (p-value = 0.037). Moreover,
PrPC modulates type I interferon signaling
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Fig 2. Interferon-responsive genes dominate among the differentially expressed genes in goats
lacking PrPC. Graphical presentation of (A) the total number and percentage of differentially expressed
genes (DEGs) between the two genotypes, compared to the average total number of genes expressed in
peripheral blood mononuclear cells from both genotypes, and (B) the total number of upregulated and
PrPC modulates type I interferon signaling
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STAT1 mRNA expression levels did not differ between the genotypes. One hour after LPS
challenge, the mRNA expression level of interferon-responsive genes increased slightly and the
difference between the two genotypes was more pronounced (Fig 4B), with three genes show-
ing a statistically significant difference in expression level (ISG15 (p-value = 0.049), IFIT1 (p-
value = 0.02), and MX1 (p-value = 0.019), assessed by multiple t-tests).
Discussion
Similar to observations in transgenic mice [6], goats [36], and cattle [27] with knockout (KO)
of PRNP, the PRNPTer/Ter goats display no obvious loss-of-function phenotype [25, 26]. Conse-
quently, only subtle transcriptomic alterations were expected, corroborating data from KO
mouse models [37–41]. Accordingly, this study revealed subtle expression differences affecting
less than a percent of the expressed genes. However, analysis of the annotated DEGs using the
Interferome database [33], identified a distinct expression profile, with 70 percent of the DEGs
being classified as interferon responsive, of which several were among the top upregulated
genes. Importantly, animals were age-matched and derived from the same research flock. The
health status of this herd is frequently monitored and considered excellent. Prior to sampling,
animals were assessed clinically by a veterinarian and found healthy, which was also confirmed
by hematological analysis in an accompanying study [26]. Furthermore, we were unable to
detect any differences in gene expression levels of neither interferons nor IFN signaling com-
ponents. A flanking gene problem will also be present in the PRNPTer/Ter goats; however, pre-
liminary data indicate that this is very limited compared to inbred knockout mouse models. In
the absence of alternative explanations, we consider the observed gene expression profile to be
a true signature of PrPC loss-of-function. It is likely that this profile, which is evident at rest in
the outbred and immunocompetent goats, might be even weaker or absent in inbred trans-
genic mice, housed in pathogen-depleted environments. It is, however, interesting to note that
studies of prion disease in mice have revealed a gene expression profile similar to that observed
in PrPC-deficient goats. Analysis of transcripts from mouse whole brain throughout the course
of experimental CJD revealed an upregulation of several interferon-responsive genes, e.g. OAS,
ISG15, and IRF-family members. Importantly, the upregulation of these genes occurred very
early in the course of the disease, approximately 50 days before the onset of neuropathological
signs and detection of PrPSc [42]. Similar findings were recently reported in another study of
prion-infected mice [43]. In a hamster model of scrapie, several interferon-responsive genes,
including those encoding OAS and Mx protein, were upregulated during development of scra-
pie [44]. In addition, three interferon-responsive genes, assessed by qPCR studies, were mod-
erately upregulated in a hamster model and different mouse models inoculated with scrapie
strains [45]. Recently, transcriptomic data from cerebellar organotypic cultured slices infected
with prions showed that a slight upregulation of several interferon-responsive genes was evi-
dent at 38 and 45 days post infection [46]. It is tempting to speculate that some of the observed
gene expression alterations at very early stages of prion disease could, at least partly, reflect
induced loss-of-PrPC function, and, thus, explain the similarity with the expression profile
reported here. Further investigations are clearly needed to test this hypothesis.
Studies of human SH-SY5Y neuroblastoma cells transfected with human PRNP displayed
a significantly dampened response (MX2 expression) to a low-level IFN-α stimulation,
downregulated annotated DEGs. The fraction of upregulated (red) and downregulated (blue) interferon-
responsive genes among the DEGs are also shown. (C) Hierarchical clustering of the interferon-responsive
genes among the DEGs and expression data from all individual goats of both genotypes. Hierarchical
clustering was performed using the ward algorithm on log2-normalized fold changes.
https://doi.org/10.1371/journal.pone.0179881.g002
PrPC modulates type I interferon signaling
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Table 1. Mean unique reads of genes related to Interferon signaling from PRNP+/+ (n = 8, ± SEM) and PRNPTer/Ter (n = 8, ± SEM) goats.
Gene symbol Transcript ID PRNP+/+ PRNPTer/Ter
Interferons
IFNA-H-like XM_005683618.1 0.3 ± 0.3 0.0 ± 0.0
IFNB2-like XM_005702021.1 63.0 ± 5.3 43.4 ± 4.2 *
IFNK XM_005683589.1 0.1 ± 0.1 0.0 ± 0.0
IFNO1-like XM_005683620.1 26.5 ± 6.8 19.1 ± 4.9
IFNT2A XM_005683606.1 0.9 ± 0.4 0.9 ± 0.5
IFNG XM_005680208.1 38.4 ± 10.9 27.8 ± 4.5
IFNL3 XM_005692539.1 0.1 ± 0.1 0.0 ± 0.0
IFNL4-like XM_005692540.1 0.5 ± 0.3 0.3 ± 0.2
Interferon receptors
IFNAR1 XM_005674742.1 11565.5 ± 613.5 11818.3 ± 683.0
IFNAR2 XM_005674684.1 3484.1 ± 245.4 3664.9 ± 188.7
IFNGR1 XM_005684807.1 3056.4 ± 268.9 3772.4 ± 252.6
IFNGR2 XM_005674741.1 7492.8 ± 179.1 8209.5 ± 408.9
IFNLR1 XM_005677011.1 95.5 ± 10.8 122.4 ± 22.4
Interferon signaling components
JAK1 XM_005678310.1 31579.9 ± 920.9 31909.0 ± 908.7
JAK2 XM_005683698.1 2399.1 ± 109.3 2587.5 ± 84.7
JAK3 XM_005682189.1 11636.9 ± 600.5 9816.8 ± 603.9
TYK2 XM_005682457.1 4528.3 ± 205.6 4775.3 ± 328.4
STAT1 XM_005676277.1 26477.4 ± 2414.9 28314.6 ± 1119.4
STAT2 XM_005680347.1 5548.9 ± 332.1 6363.6 ± 408.4
STAT3 XM_005693850.1 98.5 ± 10.5 92.5 ± 8.2
STAT4 XM_005676278.1 2101.9 ± 158.6 1949.5 ± 120.6
STAT5A XM_005693847.1 5250.6 ± 172.7 5365.3 ± 194.9
STAT5B XM_005693846.1 4604.1 ± 137.3 4511.0 ± 155.2
STAT6 XM_005680308.1 15197.3 ± 704.8 15596.6 ± 692.7
IRF1 XM_005682621.1 12308.6 ± 1155.2 10936.5 ± 1329.5
IRF2 XM_005698710.1 624.5 ± 26.6 663.4 ± 17.1
IRF3 XM_005692726.1 1073.9 ± 74.3 1169.1 ± 60.4
IRF4 XM_005696935.1 1482.5 ± 157.3 1379.5 ± 140.9
IRF5 XM_005679456.1 764.9 ± 61.4 811.8 ± 65.6
IRF6 XM_005691036.1 7.3 ± 2.2 5.4 ± 1.9
IRF8 XM_005691907.1 3565.8 ± 219.0 3824.8 ± 210.8
IRF9 XM_005685224.1 205.8 ± 16.7 234.5 ± 28.2
Inhibitors and enhancers
IRF2BP-like XM_005686182.1 2686.3 ± 135.5 2794.5 ± 123.7
IRF2BP1 XM_005692789.1 1265.3 ± 33.0 1232.4 ± 32.3
IRF2BP2 XM_005699013.1 8090.8 ± 600.5 8588.9 ± 793.4
PIAS1 XM_005685148.1 1266.8 ± 66.9 1320.0 ± 86.4
PIAS2 XM_005697179.1 390.6 ± 16.9 405.0 ± 19.2
PIAS3 XM_005677741.1 99.1 ± 7.8 99.5 ± 8.1
PIAS4 XM_005682570.1 39.4 ± 2.7 40.0 ± 4.8
SOCS2 XM_005679820.1 0.8 ± 0.4 1.4 ± 0.6
SOCS3 XM_005694412.1 372.0 ± 48.8 346.4 ± 47.5
SOCS4 XM_005685884.1 845.4 ± 24.5 823.3 ± 28.0
SOCS5 XM_005686570.1 1748.9 ± 82.0 1737.6 ± 75.8
(Continued )
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compared with untransfected cells that are virtually devoid of PrPC. Furthermore, in an inde-
pendent, parallel study involving older goat kids than those recruited for the RNA seq study,
animals were challenged with LPS, which is a potent pro-inflammatory compound. In contrast
to mice, which are relatively tolerant towards LPS, goats have a similar sensitivity as humans
[34, 35]. In line with data from the present RNA sequencing study, resting state expression lev-
els of interferon-responsive genes in leukocytes were slightly elevated in the PRNPTer/Ter geno-
type. Interestingly, the expression differences between the genotypes were increased one hour
after LPS injection. Apparently, leukocytes without the expression of PrPC upregulated inter-
feron-responsive genes more rapidly than their PrPC-expressing counterparts. The regulation
of interferon-responsive genes expression level is multifaceted and tightly controlled at several
levels [47, 48], involving receptor downregulation, upregulation of a plethora of inhibitors as
well as epigenetic modifications.
Table 1. (Continued)
Gene symbol Transcript ID PRNP+/+ PRNPTer/Ter
SOCS6 XM_005709580.1 137.5 ± 14.4 144.6 ± 14.0
SOCS7 XM_005709575.1 2286.3 ± 193.8 2144.5 ± 198.7
IL18 XM_005689450.1 21.3 ± 4.5 18.9 ± 3.6
PTK2 XM_005688815.1 82.4 ± 11.4 92.1 ± 7.4
PTK2B XM_005684041.1 99.3 ± 11.6 114.5 ± 17.5
*: p = 0.025
https://doi.org/10.1371/journal.pone.0179881.t001
Fig 3. PrPC suppresses upregulation of MX2 gene expression upon INF-α stimulation in SH-SY5Y
cells. Untransfected human neuroblastoma SH-SY5Y cells and seven different clones transfected with a
plasmid containing human PRNP to produce SH-SY5Y clones expressing human PrPC, were stimulated for
3h with IFN-α (3 U/ml) (mean ± SEM, n = 4), and MX2 gene expression was assessed. Six out of seven clones
displayed a significantly lower response to IFN-α compared with the untransfected SH-SY5Y cells, using
Dunnett’s post hoc test for multiple comparisons.
https://doi.org/10.1371/journal.pone.0179881.g003
PrPC modulates type I interferon signaling
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Taken together, our data suggest that PrPC contributes to dampening of type I interferon
signaling at rest and that loss of PrPC induces a primed state of interferon-responsive genes.
Accordingly, direct or indirect stimulation of type I IFN signaling, elicits a somewhat stronger
immediate response when PrPC is absent. These data do not conflict with roles acclaimed to
the prion protein. Indeed, they might strengthen previous observations and provide mechanis-
tic hints of PrPC physiology.
Material and methods
Animals
The animals (FOTS approval number ID 8058) included in the study were of the Norwegian
Dairy Goat Breed obtained from a research herd of approximately 100 winter-fed goats at the
Norwegian University of Life Sciences. Based on health surveillance through membership in
the Goat health monitoring service and The Norwegian Association of Sheep and Goat Farm-
ers and daily monitoring, the general health status of the herd is considered to be good. The
entire flock was previously genotyped [25] concerning PRNP genotypes, and through selective
breeding, goat kids with the two genotypes PRNP+/+ (n = 8; 4 female and 4 male) and PRNPTer/
Ter (n = 8; 4 female and 4 male) were retrieved. Prior to inclusion in the experiment, all goat
kids were examined clinically and found to be healthy.
Isolation of peripheral blood mononuclear cells
Blood was sampled from the jugular vein into EDTA tubes at 2–3 months of age. Peripheral
blood mononuclear cells (PBMCs) were isolated by gradient centrifugation (Lymphoprep1,
Axis-Shield, Dundee, Scotland) at 1760 x g without brake, and washed with PBS supplemented
with EDTA (2 mM). Red blood cells were lysed by brief exposure to sterile water, and washed
with PBS supplemented with EDTA (2 mM) prior to counting and trypan blue viability assess-
ment using a Countess1 Automated Cell Counter (Life Technologies, Thermo Fisher Scien-
tific, Waltham, MA).
Fig 4. Expression of interferon-responsive genes in blood leukocytes after in vivo lipopolysaccharide (LPS) challenge in
goats without PrPC. RNA was extracted from circulating blood leukocytes from both genotypes, and gene expression was analyzed
by FLUIDIGM qPCR. (A) Basal expression level (0 h) of selected interferon-responsive genes and STAT1 in PRNP+/+ (n = 12) and
PRNPTer/Ter (n = 13) animals. (B) Gene expression of interferon-responsive genes and STAT1 after in vivo LPS challenge (1 h) from
PRNP+/+ (n = 7) and PRNPTer/Ter (n = 8) animals. Values are mean ± SEM. Statistical significance is indicated by *, p-value < 0.05, as
assessed by multiple t-tests.
https://doi.org/10.1371/journal.pone.0179881.g004
PrPC modulates type I interferon signaling
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Cell culture studies
Human neuroblastoma SH-SY5Y cells (Sigma-Aldrich, Merck, Kenilworth, NJ) were cultured
in Eagle’s Minimum Essential Medium and Ham’s F12 (1:1) (Sigma-Aldrich) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), glutamine and antibiotics (1% streptomy-
cin and penicillin) (all from Gibco, Thermo Fisher Scientific), and cultivated in T25 flasks at
37˚C with 5% (v/v) CO2 at saturated humidity. SH-SY5Y cells were stably transfected with a
plasmid construct, pCI-neo (Promega, Madison, WI) encoding human PRNP, using jetPRIME
(Polyplus, Illkirch, France) according to the manufacturer’s instructions. Transfected cells
were grown under selection pressure of Geneticin (Thermo Fisher Scientific), and nine differ-
ent single clones with variable levels of PrPC (SH-SY5Y PrPhigh) were isolated (S4 Fig). Clone
no. 8 showed an abnormal phenotype, and was excluded from the studies.
Western blotting
Untransfected SH-SY5Y cells and transfected SH-SY5Y PrPhigh clones were lysed in ho-
mogenizer buffer (Tris HCl 50 uM, NaCl 150 mM, EDTA 1 mM, DOC 0.25%, NP40 1%) sup-
plemented with protease inhibitor cocktail (Roche complete, Roche Holding AG, Basel,
Switzerland). Protein concentrations were measured using Protein assay (Bio-Rad, Hercules,
CA). To obtain deglycosylated protein, 20 μg of total protein were incubated overnight with
PNGase-F (New England Biolabs, Ipswich, MA), according to the manufacturer’s instructions.
Fifty μg of protein or the deglycosylated samples were separated on sodium dodecyl sulfate
(SDS) polyacrylamide gel electrophoresis (12% Criterion™ XT Bis-Tris, Bio-Rad), and trans-
ferred to polyvinylidene fluoride (PVDF) membranes (GE Healthcare, Little Chalfont, United
Kingdom). After incubation with blocking buffer (5% non-fat milk in TBS-Tween) for 90 min-
utes at room temperature, samples were incubated in 1% non-fat milk in TBS-Tween contain-
ing mouse anti-PrPC primary antibody diluted 1:4000 (6H4, Prionics, Thermo Fischer
Scientific) over-night at 4˚C. Subsequently, the membrane was washed and incubated for 90
minutes in 1% non-fat milk containing Alkaline Phosphatase (AP)-conjugated anti-mouse
IgG diluted 1:4000 (Novex, Life Technologies, Thermo Fischer Scientific). Membrane was
developed using EFC™ substrate (GE Healthcare) and visualized with Typhoon 9200 (Amer-
sham Bioscience, GE Healthcare).
Isolation and sequencing of RNA
Total RNA was extracted using the Qiagen RNeasy mini plus kit (Qiagen, Germantown, MD)
following the manufacturer’s instructions. RNA concentration and purity was analyzed using
NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific) or Epoch Microplate Spectro-
photometer (BioTek Instruments Inc, Winooski, VT), and quality was assessed before RNA
sequencing using RNA Nano Chips on an Agilent 2100 Bioanalyzer (both from Agilent Tech-
nologies, Santa Clara, CA). RNA was stored at -80˚C. Individual RNA samples of high quality
(RIN 9.8) were sequenced by mRNA poly-A-tail, paired-end sequencing (Illumina HiSeq
2000) with 91 bp read-lengths (Beijing Genomics Institute (BGI), Hong Kong), retrieving a
minimum depth of 5G clean data per sample. In detail, after the total RNA extraction and
DNase I treatment, magnetic beads with Oligo (dT) were used to isolate mRNA. Mixed with
the fragmentation buffer, the mRNA was fragmented into short fragments, and cDNA was
synthesized using the mRNA fragments as templates. Short fragments were purified and
resolved with EB buffer for end reparation and single nucleotide A (adenine) addition. The
short fragments were connected with adapters. After agarose gel electrophoresis, the suitable
fragments were selected for the PCR amplification as templates. During the QC steps, Agilent
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2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System were used in quantification
and qualification of the sample library.
For the IFN-studies, RNA quality was assessed by TAE/formamide RNA gel electrophore-
sis. RNA samples were mixed with formamide (50% v/v, Sigma) and orange loading dye (New
England Biolabs), denatured by heating for 5 min at 65˚C, put on ice, and loaded on 1% aga-
rose gel containing 1xTAE buffer (0.04 M Tris-acetate, 1 mM EDTA) and visualized with
SYBR™ Safe (Invitrogen, Thermo Fisher Scientific).
Analysis of RNA sequencing data
Reads were mapped to the goat genome assembly (CHIR_1.0) using SOAP2 [49]. Reads
per gene were obtained using SOAP2 and the goat genome annotation (RefSeq, CHIR_1.0).
Read counts were normalized to reads per kilobase per million mapped reads (RPKM) [50].
Testing for differentially expressed genes was performed using the function exactTest in edgeR
[32].
Expression analysis by reverse transcription (RT) quantitative real-time
PCR (qPCR) analysis
cDNA was synthesized using SuperScript III Reverse Transcriptase, RNase Out, dNTP mix
and Random Primers (all from Invitrogen, Thermo Fisher Scientific) at the following condi-
tions: 5 min at 65˚C,>1 min on ice, 5 min at 25˚C, 1 h at 50˚C and 15 min at 70˚C.
For the RNA sequencing validation study, qPCR was conducted with LightCycler 480 Sybr
Green I Master mix (Roche). cDNA corresponding to 2.5 ng RNA was used per reaction. The
samples were run in duplicates in a total volume of 20 μl on a LightCycler 96 System (Roche).
Conditions: 5 min at 95˚C; 40 cycles of 10 sec at 95˚C, 10 sec at 60˚C and 10 sec at 72˚C; and
melting curve with 5 sec at 95˚C, 1 min at 65˚C and 97˚C. Relative expression levels were cal-
culated using a standard curve generated from one randomly selected animal, run in triplicate,
with GAPDH as a reference gene, and one randomly selected animal as a positive control. The
average of six PRNPTer/Ter animals was divided by the average of six PRNP+/+ animals, and
compared relative to RNA sequencing data.
For the interferon-treatment studies using SH-SY5Y cells, qPCR was conducted with Light-
Cycler 480 Sybr Green I Master mix (Roche). cDNA corresponding to 10 ng RNA was used
per reaction. The samples were run in triplicate in a total volume of 10 μl on a LightCycler 96
System (Roche). Conditions: 5 min at 95˚C; 40 cycles of 10 sec at 95˚C, 10 sec at 60˚C and 10
sec at 72˚C; and melting curve with 5 sec at 95˚C, 1 min at 65˚C and 97˚C. Relative expression
levels were calculated using the ΔΔCt method. ActB was used as a reference gene. An inter-run
calibrator was included on every plate as a positive control. The qPCR-amplified sample was
run on a 1% agarose gel, and visualized using SYBR™ Safe (Thermo Fisher Scientific).
LPS challenge and FLUIDIGM qPCR of whole blood leukocyte
interferon-responsive genes
An intravenous LPS challenge was performed (0.1 μg/kg, Escherichia coli O26:B6) in 16 Nor-
wegian dairy goats age 6–7 months (8 PRNP+/+ (female) and 8 PRNPTer/Ter (7 female, 1 cas-
trated male)) (FOTS approval number IDs 5827, 6903, and 7881), and 10 controls were
included (5 of each genotype). In brief, blood samples were collected in PAX-gene blood RNA
tubes before (0 h) and after LPS challenge (1 h). High quality RNA (RIN 9.0 ± 0.34) was
extracted using the PAXgene Blood miRNA kit, and cDNA synthesis was performed in two
replicates (QuantiTect Reverse Transcription Kit). The relative expression of ISGs in
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circulating leukocytes was assessed after qPCR on the Fluidigm Biomark HD platform and
data analysis using GenEx5 software (MultiD, Sweden). The full study protocol, method
description, and primer sequences can be found in [34, 35].
Statistical analysis
Multiple t-tests or two-way ANOVA followed by Dunnett’s post hoc test for multiple compari-
sons were used for statistical analysis of the data using Graph Pad Prism v. 6.07 (Graphpad, La
Jolla, CA). For correlation analysis, the Pearson correlation coefficient was calculated. Mean
values are presented ± SEM.
Ethics statement
The animal experiments were performed in compliance with ethical guidelines, and approved
by the Norwegian Animal Research Authority (FOTS approval number IDs 8058, 5827, 6903,
and 7881) with reference to the Norwegian regulation on animal experimentation (FOR-2015-
06-18-761).
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S1 Fig. Individual number of reads obtained from RNA sequencing. Total reads, total
mapped reads and uniquely mapped reads across all samples, n = 16, 8 of each genotype.
(TIF)
S2 Fig. Hierarchical clustering dendrogram. Hierarchical clustering dendrogram of all genes
after normalization of expression data (RPKM) using Euclidean distance and complete link-
age.
(TIF)
S3 Fig. Chromosomal distribution of differentially expressed genes. (A) Frequency of dif-
ferentially expressed genes (735 genes) per chromosome. Total number of genes per chromo-
some were obtained from National Center for Biotechnology Information (NCBI), based on
the Capra hircus CHIR_1.0-Primary Assembly. (B) Chromosomal distribution of annotated
differentially expressed genes (86 genes).
(TIF)
S4 Fig. Clones of human neuroblastoma SH-SY5Y cells expressing human PRNP. Protein
expression of PrPC for untreated and PNGase-F-treated untransfected human neuroblastoma
SH-SY5Y cells and SH-SY5Y clones transfected with human PRNP (n = 8), determined by
Western Blot analysis using 6H4 mouse anti-PrPC as the primary antibody. Protein bands cor-
respond to glycosylated PrPC, deglycosylated PrPC and PrPC C1 fragment as indicated.
(TIF)
S1 Table. Forward and reverse primers used for qPCR.
(DOCX)
S2 Table. Differentially expressed genes between PRNPTer/Ter (n = 8) and PRNP+/+ (n = 8)
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